- Home
- PTGX
as 05-30-2025 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 2.9B | IPO Year: | 2016 |
| Target Price: | $66.50 | AVG Volume (30 days): | 760.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.86 | EPS Growth: | -68.10 |
| 52 Week Low/High: | $27.00 - $60.60 | Next Earning Date: | 05-06-2025 |
| Revenue: | $207,801,000 | Revenue Growth: | -34.02% |
| Revenue Growth (this year): | -81.63% | Revenue Growth (next year): | 50.30% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ali Asif | PTGX | Chief Financial Officer | Apr 22 '25 | Sell | $46.00 | 1,756 | $80,776.00 | 61,065 | |
| Waddill William D. | PTGX | Director | Mar 17 '25 | Sell | $54.25 | 4,000 | $217,000.00 | 13,130 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Mar 13 '25 | Sell | $55.74 | 30,514 | $1,700,850.36 | 83,892 | |
| Ali Asif | PTGX | Chief Financial Officer | Mar 12 '25 | Sell | $58.73 | 24,903 | $1,462,553.19 | 61,065 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
ACCESS Newswire
10 days ago
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Argus Research
17 days ago
PTGX: Raising target price to $49.00
Insider Monkey
22 days ago
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain
MT Newswires
22 days ago
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study
ACCESS Newswire
22 days ago
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Simply Wall St.
23 days ago
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Argus Research
24 days ago
PTGX: Rating increased to a BUY
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.